Treatment Week Sofosbuvir + Weight-based RBV n=10 (ITT analysis) Sofosbuvir + Weight-based RBV n=9 (per protocol analysis) 24 week treatment period -N % (95% CI) 4 post treatment period -N % (95% CI) 2
0 Laboratory abnormality -Anemia Grade 1 (10.0-10.9 g/dL) 1 (10) Grade 2 (9.0-9.9 g/dL) 3 (30) Grade 3 (7.0-8.9 g/dL) 0 -Hyperbilirubinemia Grade 1 (1.1-1.5 x ULN) 1 (10) Grade 2 (1.6-2.5 x ULN) 1 (10) Grade 3 (2.5-5 x ULN) 0 -Hypophosphatemia Grade 2 (2.0-2.4 mg/dL) 1 (10) Grade 3 (1.0-1.9 mg/dL) 1 (10) -Neutropenia Grade 3 (500-749/mm3) 0 Hypocalcemia (<2.04 mmol/L) 1 (10) Hypomagnesemia (<0.63 mml/L) 2 (20) Elevated serum creatinine (>1.1x ULN) 0
All adverse events that occurred during the study in at least 2 subjects in any group are included regardless of relatedness to study drug. Weight based ribavirin: 1000-1200mg/day,: Low dose ribavirin: 600mg/day. e Fitted curves for hepatitis C viral kinetics (VK) in 50 randomized participants (a and b), pharmacokinetics and pharmacodynamics (PK-PD) in 20 randomized participants (c), and pharmacodynamics and viral kinetic (PD-VK) in 20 randomized participants (d).
(a) The median fitted curves are plotted for viral decay (VK) with the overall median plotted in blue. (b) The median viral decay curves were rapid and independent of ribavirin dosing (c) The median value of mean efficiency of drug blocking viral production in the PK-PD model was similar in SVR vs. relapsers (p=0.26) (d) The PK-VK model for viral decay showed a significantly higher loss rate of infectious virus in patients who achieved SVR compared to relapsers , (p=0.009) Abbreviations: SVR: Sustained virologic responders; pharmacokinetics (PK); pharmacodynamics (PD); viral kinetics (VK).
Details of the VK/PK/PD modeling are as below:
Pharmacokinetics (PK) : Used Bateman function using parameters k₁ and k₂ for drug absorption and elimination.
Pharmacodynamics (PD): Used an intermediate compartment Z defined by
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Viral kinetic (VK): based on the general model for HCV viral kinetics
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Data was fitted by maximum likelihood method accounting for data below the quantitation limits.For the VK model without using a PK-PD approach, only a constant drug effectiveness, infected cell loss rate and baseline viral load were fitted. Loss rate of free virus c was fixed to 5/day, regeneration rate γ to 3/day, proliferation p to 3/day, and ribavirin effect ρ was 60%. Further parameters were obtained from steady state conditions before treatment started. For a full PK-PD approach, the same parameter assumptions were used; additionally, the rate a for the intermediate compartment was log (2)/2/day and the hill parameter was 1. Percentage of participants who experienced a hemoglobin drop of >2g/dL by a certain timepoint. There was significantly higher proportion of participants on weight based RBVwho experienced Hgb drop >2g/dl at week 4 and week 12 compared to low dose RBV. Hgb: hemoglobin. WBR: Weight based ribavirin: 1000-1200mg/day; LDR Low dose ribavirin: 600mg/day,
